Matinas BioPharma Holdings Inc. (MTNB) and CohBar Inc. (NASDAQ:CWBR) Comparison side by side

We are comparing Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB) and CohBar Inc. (NASDAQ:CWBR) on their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Matinas BioPharma Holdings Inc. N/A 736.40 14.87M -0.16 0.00 CohBar Inc. N/A 0.00 14.35M -0.35 0.00 In table 1 we can see Matinas BioPharma Holdings Inc. and CohBar Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows Matinas BioPharma Holdings Inc. and CohBar Inc.’s return on equity, return on assets and net margins. Net Margins Return on Equity Return on Assets Matinas BioPharma Holdings Inc. 0.00% 0% -104.5% CohBar Inc. 0.00% -96.8% -80.6% Risk and Volatility

Matinas BioPharma Holdings Inc.’s current beta is 1.01 and it happens to be 1.00% more volatile than Standard & Poor’s 500. In other hand, CohBar Inc. has beta of 1.06 which is 6.00% more volatile than Standard & Poor’s 500.

Liquidity

Matinas BioPharma Holdings Inc.’s Current Ratio is 2.9 while its Quick Ratio is 2.9. On the competitive side is, CohBar Inc. which has a 33.2 Current Ratio and a 33.2 Quick Ratio. CohBar Inc. is better positioned to pay off short and long-term obligations compared to Matinas BioPharma Holdings Inc.

Insider & Institutional Ownership

The shares of both Matinas BioPharma Holdings Inc. and CohBar Inc. are owned by institutional investors at 5.8% and 9.6% respectively. About 4.1% of Matinas BioPharma Holdings Inc.’s share are held by insiders. On the other hand, insiders held about 4.5% of CohBar Inc.’s shares.

Performance

In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Matinas BioPharma Holdings Inc. -11.14% -15.72% 70.45% 26.5% -46.04% -35.34% CohBar Inc. -12.47% -9.37% -24.31% -61.17% -22.17% -27.97% For the past year CohBar Inc. has weaker performance than Matinas BioPharma Holdings Inc.

Summary

CohBar Inc. beats Matinas BioPharma Holdings Inc. on 4 of the 7 factors.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat AlzheimerÂ’s disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat AlzheimerÂ’s disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.

Tags:, ,

Add a Comment

Your email address will not be published.